COMPANY
Novartis
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Head DDIT ISC Software Development Governance, Integrity & Secure Software Development Life Cycle (SDLC) | Prague | Oct 23, 2026 | Oct 12, 2026 |
| Head DDIT ISC Software Development Governance, Integrity & Secure Software Development Life Cycle (SDLC) | Barcelona Gran Vía | Oct 23, 2026 | Oct 12, 2026 |
| Head DDIT ISC Software Development Governance, Integrity & Secure Software Development Life Cycle (SDLC) | Hyderabad | Oct 23, 2026 | Oct 12, 2026 |
| Laboratorijski analitik III (m/ž/d) | Mengeš | Oct 23, 2026 | Oct 12, 2026 |
| Director DDIT IES CHS AWS Engineering | Hyderabad | Oct 23, 2026 | Oct 14, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07811869, actual start Oct 7, 2026) (+14 other new trials); 30 clinical-operations roles open. ClinicalTrials.gov NCT07811869 (Oct 7, 2026)
Evidence (15 events)
- Oct 7, 2026 · ClinicalTrials.gov NCT07811869
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-10-07,type:ACTUAL}; studyFirstPostDate=2026-09-10; briefTitle='A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin ' - Sep 21, 2026 · ClinicalTrials.gov NCT07816328
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-21,type:ACTUAL}; studyFirstPostDate=2026-09-11; briefTitle='Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately ' - Sep 1, 2026 · ClinicalTrials.gov NCT07625306
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=WITHDRAWN; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-06-04; briefTitle='Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL' - Aug 27, 2026 · ClinicalTrials.gov NCT07768371
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A 52-week Study of Remibrutinib in IgE-mediated Food Allergy' - Aug 24, 2026 · ClinicalTrials.gov NCT07700056
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle='A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (' - Aug 6, 2026 · ClinicalTrials.gov NCT07498335
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-06,type:ACTUAL}; studyFirstPostDate=2026-03-27; briefTitle='Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN' - Aug 4, 2026 · ClinicalTrials.gov NCT05776927
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-04,type:ACTUAL}; studyFirstPostDate=2023-03-20; briefTitle='A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol ' - Sep 29, 2026 · ClinicalTrials.gov NCT07775924
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-29,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus' - Sep 18, 2026 · ClinicalTrials.gov NCT07830719
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-18,type:ACTUAL}; studyFirstPostDate=2026-09-21; briefTitle='Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP' - Aug 24, 2026 · ClinicalTrials.gov NCT07737743
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-07-30; briefTitle="A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease" - Aug 4, 2026 · ClinicalTrials.gov NCT07421167
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-04,type:ACTUAL}; studyFirstPostDate=2026-02-19; briefTitle="A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients " - Jul 30, 2026 · ClinicalTrials.gov NCT07681271
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-02; briefTitle='A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea ' - Sep 8, 2026 · ClinicalTrials.gov NCT07801508
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-09-03; briefTitle='A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors' - Sep 2, 2026 · ClinicalTrials.gov NCT07783503
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-08-24; briefTitle='A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participan' - Aug 27, 2026 · ClinicalTrials.gov NCT07448610
leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-03-04; briefTitle='ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-br'
- Oct 7, 2026 · ClinicalTrials.gov NCT07811869
Raises and deals from press releases
- Deal Deal · $1.1B · announced Jul 6, 2026 Company release ↗
Source quote
- Jul 6, 2026 · Company release ↗
“Transaction Details Under the terms of the agreement, Novartis will pay USD 1.1bn upfront, with up to USD 400m in potential milestone payments to acquire Myricx Bio.”
- Jul 6, 2026 · Company release ↗
Timeline
- Trial start Phase 3: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy source ↗
- Trial start —: A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait source ↗
- Trial start Phase 2: A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period source ↗
- Trial start Phase 2: A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies source ↗
- Trial start Phase 1: A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS source ↗
- Trial start —: A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates source ↗
- Trial start —: A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain source ↗
- Trial start Phase 3: Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks source ↗
- Trial start Phase 2: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) source ↗
- Trial start Phase 1: A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies source ↗
- Trial start Phase 1: Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation source ↗
- Trial start Phase 1/Phase 2: Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments source ↗
- Trial start Phase 1: Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer source ↗
- Trial start 3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) source ↗
- Trial start —: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany source ↗
- Trial start Phase 1: A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction source ↗
- Trial start I: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Pros source ↗
- Trial start Phase 1/Phase 2: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors source ↗
- Trial start —: A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment source ↗
- Trial start I: A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC source ↗
- Trial start I: Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors source ↗
- Trial start Phase 2: A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation source ↗
- Trial start II: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate source ↗
- Trial start II: EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) source ↗
- Trial start Phase 1: Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). source ↗
Upcoming milestones
- Oct 26, 2026 (ESTIMATED) · Phase 3 · Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-ob · NCT05360446
- Nov 3, 2026 (ESTIMATED) · Phase 3 · 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional · NCT05677451
- Dec 8, 2026 (ESTIMATED) · Phase 1 · A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction · NCT07465653
- Dec 15, 2026 (ESTIMATED) · · A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain · NCT07598448
- Dec 15, 2026 (ESTIMATED) · · A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment · NCT07786077
- Dec 21, 2026 (ESTIMATED) · Phase 1 · Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation · NCT07626281
- Jan 28, 2027 (ESTIMATED) · Phase 3 · Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aroma · NCT05038735
- Mar 30, 2027 (ESTIMATED) · · A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait · NCT07454850
Clinical trials (lead sponsor) Showing 50 of 1,999
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active, not recruiting | Jul 3, 2025 | Jul 16, 2027 (estimated) |
| NCT05948943 | Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/Phase 3 | Recruiting | Nov 24, 2023 | May 31, 2028 (estimated) |
| NCT07357727 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | 3 | Recruiting | May 27, 2026 | May 17, 2028 (estimated) |
| NCT07421167 | A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Aug 4, 2026 | Jan 18, 2029 (estimated) |
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | III | Recruiting | Feb 28, 2024 | Sep 7, 2029 (estimated) |
| NCT07868328 | A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies | Phase 2 | Not yet recruiting | Oct 23, 2026 | Mar 26, 2029 (estimated) |
| NCT07468071 | Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments | Phase 1/Phase 2 | Active, not recruiting | Jun 8, 2026 | Jun 11, 2029 (estimated) |
| NCT07206056 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | II | Recruiting | Oct 15, 2025 | Nov 9, 2029 (estimated) |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer | Phase 3 | Active, not recruiting | Dec 7, 2018 | May 29, 2030 (estimated) |
| NCT06546670 | A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease | I | Recruiting | Aug 15, 2024 | May 1, 2028 (estimated) |
| NCT07226986 | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | I | Recruiting | Dec 5, 2025 | Jul 10, 2028 (estimated) |
| NCT06991556 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Active, not recruiting | Jul 7, 2025 | Mar 15, 2032 (estimated) |
| NCT06997588 | EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) | II | Recruiting | Oct 9, 2025 | Jan 29, 2029 (estimated) |
| NCT07604571 | Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer | Phase 1 | Recruiting | May 28, 2026 | Jun 8, 2032 (estimated) |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Phase 4 | Recruiting | Jan 26, 2018 | Dec 28, 2032 (estimated) |
| NCT07340190 | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies | Phase 1 | Recruiting | Jun 12, 2026 | Mar 9, 2028 (estimated) |
| NCT04641442 | Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations | Phase 2 | Active, not recruiting | Dec 18, 2020 | Oct 14, 2025 (actual) |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | I | Recruiting | Nov 24, 2025 | May 9, 2029 (estimated) |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Phase 4 | Active, not recruiting | Jul 7, 2022 | Jun 28, 2030 (estimated) |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Phase 1/Phase 2 | Recruiting | Dec 29, 2025 | May 9, 2031 (estimated) |
| NCT05445843 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | Phase 2 | Active, not recruiting | Dec 6, 2022 | Nov 4, 2024 (actual) |
| NCT07549516 | A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany | Not listed | Recruiting | Apr 17, 2026 | Sep 30, 2030 (estimated) |
| NCT04589650 | Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum | Phase 2 | Active, not recruiting | Apr 19, 2021 | Mar 20, 2024 (actual) |
| NCT06813911 | Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD | Phase 3 | Active, not recruiting | Apr 30, 2025 | Feb 3, 2028 (estimated) |
| NCT07598448 | A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain | Not listed | Recruiting | Sep 22, 2026 | Dec 15, 2026 (estimated) |
| NCT02555683 | Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. | Phase 3 | Completed | Dec 11, 2015 | Oct 21, 2019 (actual) |
| NCT04230148 | Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). | Phase 4 | Completed | Feb 11, 2022 | Mar 27, 2026 (actual) |
| NCT06551519 | A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis | Not listed | Active, not recruiting | Oct 23, 2024 | Nov 29, 2028 (estimated) |
| NCT04557462 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | Phase 3 | Recruiting | Sep 20, 2021 | Dec 4, 2030 (estimated) |
| NCT07626281 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation | Phase 1 | Recruiting | Jun 9, 2026 | Dec 21, 2026 (estimated) |
| NCT05360446 | Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events | Phase 3 | Active, not recruiting | Jul 8, 2022 | Oct 26, 2026 (estimated) |
| NCT05677451 | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up | Phase 3 | Active, not recruiting | Jul 11, 2023 | Nov 3, 2026 (estimated) |
| NCT02445222 | CAR-T Long Term Follow Up (LTFU) Study | Phase 3 | Recruiting | Nov 2, 2015 | Apr 18, 2039 (estimated) |
| NCT07816328 | Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | Phase 3 | Recruiting | Sep 21, 2026 | Jun 2, 2028 (estimated) |
| NCT07855276 | A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS | Phase 1 | Not yet recruiting | Oct 14, 2026 | Jun 19, 2028 (estimated) |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | Phase 4 | Completed | Sep 3, 2022 | Aug 4, 2025 (actual) |
| NCT07843758 | An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine Care | Not listed | Completed | Mar 1, 2024 | Oct 1, 2025 (actual) |
| NCT07465666 | A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | Not listed | Not yet recruiting | Sep 30, 2026 | Aug 31, 2027 (estimated) |
| NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Recruiting | Aug 10, 2022 | Mar 19, 2026 (actual) |
| NCT07465653 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction | Phase 1 | Recruiting | Mar 18, 2026 | Dec 8, 2026 (estimated) |
| NCT06133972 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | 3 | Recruiting | May 21, 2024 | Apr 3, 2034 (estimated) |
| NCT07786077 | A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | Not listed | Recruiting | Dec 8, 2025 | Dec 15, 2026 (estimated) |
| NCT07454850 | A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | Not listed | Not yet recruiting | Oct 30, 2026 | Mar 30, 2027 (estimated) |
| NCT05739942 | Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma | Phase 1 | Active, not recruiting | May 15, 2024 | Aug 10, 2027 (estimated) |
| NCT07850752 | A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy | Phase 3 | Not yet recruiting | Dec 1, 2026 | Sep 17, 2028 (estimated) |
| NCT05038735 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | Phase 3 | Active, not recruiting | Dec 17, 2021 | Jan 28, 2027 (estimated) |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | I | Recruiting | Jan 13, 2026 | Aug 2, 2032 (estimated) |
| NCT07748624 | A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period | Phase 2 | Recruiting | Oct 30, 2026 | Dec 26, 2028 (estimated) |
| NCT06751238 | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). | Phase 1 | Recruiting | Sep 24, 2025 | Oct 31, 2029 (estimated) |
| NCT07217067 | A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | Phase 2 | Recruiting | Oct 28, 2025 | Sep 9, 2027 (estimated) |
Open jobs 961
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Head DDIT ISC Software Development Governance, Integrity & Secure Software Development Life Cycle (SDLC) | Prague | Oct 23, 2026 | Oct 12, 2026 | Senior |
| Head DDIT ISC Software Development Governance, Integrity & Secure Software Development Life Cycle (SDLC) | Barcelona Gran Vía | Oct 23, 2026 | Oct 12, 2026 | Senior |
| Head DDIT ISC Software Development Governance, Integrity & Secure Software Development Life Cycle (SDLC) | Hyderabad | Oct 23, 2026 | Oct 12, 2026 | Senior |
| Laboratorijski analitik III (m/ž/d) | Mengeš | Oct 23, 2026 | Oct 12, 2026 | Mid |
| Director DDIT IES CHS AWS Engineering | Hyderabad | Oct 23, 2026 | Oct 14, 2026 | Not stated |
| Sales Rep (Territory Business Executive) | Maharashtra | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Senior Analyst - Brand Analytics | Hyderabad | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Sales Representative (Territory Business Executive) | Delhi Territory | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Biocatalysis and Protein Engineering - Industrial Post Doctoral Researcher in Global Discovery Chemistry (Novartis Genesis Labs) | Basel (City) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Production Lead (m/f/d) | Halle (Saale) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Supply Chain Manager (m/f/d) | Halle (Saale) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Associate Director DDIT ISC Detection & Response | Barcelona Gran Vía | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Process Expert, Manufacturing Science & Technology | Baarle Nassau | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Junior Product Steward, Manufacturing Science & Technology | Baarle Nassau | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Portfolio Account Specialist, VIC West - Rheumatology | 2 locations (listed on the posting) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Senior Expert Engineering | Ivrea | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Operater v proizvodnji trdnih izdelkov (m/ž/d) | Ljubljana | Oct 22, 2026 | Oct 12, 2026 | Mid |
| Associate Director, Neuromuscular, US Patient Advocacy | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 12, 2026 | Senior |
| Representante de Ventas Oncología - Base Barranquilla | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 12, 2026 | Mid |
| Medical Oncology Head | Toranomon, Japan | Oct 22, 2026 | Oct 12, 2026 | Senior |
| Manager, Field Business Partner | Toranomon, Japan | Oct 22, 2026 | Oct 12, 2026 | Mid |
| Manufacturing Quality Assurance Specialist (1st Shift) | Durham | Oct 22, 2026 | Oct 12, 2026 | Mid |
| Associate Director, Access & Reimbursement (ADAR) CV- West Texas | 4 locations (listed on the posting) | Oct 22, 2026 | Oct 12, 2026 | Senior |
| Director, Medical Value & Enablement | East Hanover | Oct 22, 2026 | Oct 14, 2026 | Not stated |
| Director Medical Value & Enablement | East Hanover | Oct 22, 2026 | Oct 17, 2026 | Not stated |
| ERC Head Adriatic | Croatia | Oct 22, 2026 | Oct 20, 2026 | Not stated |
| Site Quality Head, Morrisville (Director) | Morrisville | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Order Management Specialist | INSURGENTES | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Expert Data Scientist, Human Genetics | Cambridge (USA) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Associate Director, Data Engineering Lead | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Data Analyst, MMF - Insights & Operational Excellence | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Medical Science Liaison – Oncology (Solid Tumor) – Minneapolis, MN Territory | Field Non-Sales (USA) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Business Information Security Expert, Finance | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Assoc. Dir. DDIT ISC Risk Governance & Enablement | Barcelona Gran Vía | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Principal Clinical Data Scientist | 2 locations (listed on the posting) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Director, Portfolio Scientific Communications | London, United Kingdom | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Communications Specialist | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Director, Portfolio Scientific Communications | Dublin (NOCC) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Specialist - Governance | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Manager, Digital Finance | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Manager, Business Planning & Analysis | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Associate Director Process Management | Barcelona Gran Vía | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Dir. DDIT ISC Functional Sec. Arch IAM | Barcelona Gran Vía | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Recruitment Experience Partner | Prague | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Principal Scientist I, Frontiers Target Champion | Cambridge (USA) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Tehnolog proizvodnih procesov II (m/ž/d) | Mengeš | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Operations Manager | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Financial Analyst, Business Planning & Analysis | Hyderabad | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Associate Director, Access and Reimbursement (ADAR)- Radioligand Therapies (RLT) - Washington DC & Baltimore | Field Non-Sales (USA) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Content Activation & Omnichannel Orchestration Senior Manager | Santo Amaro | Oct 22, 2026 | Oct 23, 2026 | Not stated |
Connect
See your connections at Novartis on LinkedIn (search by name, results not checked)